01736nas a2200169   4500000000100000008004100001653001900042653002100061653004400082100001200126700001400138700001400152245011800166856009400284300000800378520118000386       2024                            d10aLepra reaction10aHansen's disease10aCSCR (Central Serous Chorioretinopathy)1 aSingh T1 a Narang T1 a Yakang D00aCentral Serous Chorioretinopathy in a Patient with Hansen’s  Disease with Type 1 Lepra Reaction - A Case Report  uhttps://www.ijl.org.in/published-articles/26062024082253/9_Case_Report_TP_Singh_et_al.pdf  a1-53 a<p>Central serous chorioretinopathy (CSCR), a disorder with complex etiopathogenesis, is a significant vision-threatening disease aggravated by corticosteroid therapy and it is also shown to be associated with inflammation. We report development of CSCR in a patient with Hansen’s disease with type1 lepra reaction. 34- years- old male patient a known case of Hansen’s disease, developed blurring of vision in his left eye following treatment with multidrug therapy for leprosy with best corrected visual acuity (BCVA) 6/36 in his left eye. He was diagnosed to have left eye acute CSCR based on clinical, fundus fluorescence angiography (FFA) and optical coherence tomography (OCT) findings. The patient’s BCVA in left eye improved to 6/6 at 3months follow-up after lepra reaction subsided on continuing oral clofazimine. We can conclude that patients with Hansen’s disease are risk of developing vision threatening complications not only from anterior segment involvement but also posterior segment involvement like CSCR. Therefore, patients with lepra reaction should be followed up carefully and managed with alternative nonsteroidal agents whenever possible</p>